Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lipocine Inc.LPCN · Entity 7696 | Director · Chief Executive Officer | June 29, 2026 | June 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lipocine Inc.
Report date June 29, 2026 · Filed June 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.49 · Expires 2036-06-29 | Direct | 227,214 |
Reported balance
After 2026-06-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-29 · Grant · Acquired 52,781 · Balance 227,214 F1: Subject to vesting whereby 1/3 of the shares subject to the award will vest on June 29, 2027 while the remaining 2/3 of the shares subject to the award will vest monthly on a prorated basis over the following two years. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to vesting whereby 1/3 of the shares subject to the award will vest on June 29, 2027 while the remaining 2/3 of the shares subject to the award will vest monthly on a prorated basis over the following two years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 04, 2018 Filed Dec 6, 2018 11:01 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantRestricted stock unit · Derivative | 290,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-18-001327 · doc4_5817.xml · derivative · entry 1 Patel Mahesh V. · CIK 0001579872 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,000 Underlying: Common Stock · 290,000 shares Expires 2028-12-04 F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit F2 · derivative.exercise_date: Subject to vesting whereby 50% of the shares subject to the award will vest on the one year anniversary of December 4, 2019 and the remaining 50% of the shares subject to the award will vest on the two year anniversary of December 4, 2020. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:16 UTC | Lipocine Inc. LPCN · Entity 7696 | Exercise / conversionRestricted Stock Unit · Derivative | 15,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-18-000029 · doc4_5171.xml · derivative · entry 3 Patel Mahesh V. · CIK 0001579872 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common stock · 15,000 shares Expires 2027-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 29, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. F4 · derivative.expiration_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 29, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:16 UTC | Lipocine Inc. LPCN · Entity 7696 | SaleCommon stock | 6,000 | $3.48 | $20,866.80 |
DisclosureSEC source: 0001638599-18-000029 · doc4_5171.xml · nonDerivative · entry 2 Patel Mahesh V. · CIK 0001579872 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 722,112 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: Represents the weighted average price of shares sold at a price that ranged from $3.43-$3.55. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:16 UTC | Lipocine Inc. LPCN · Entity 7696 | Exercise / conversionCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-18-000029 · doc4_5171.xml · nonDerivative · entry 1 Patel Mahesh V. · CIK 0001579872 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 728,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4). F1 · shares: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4). F1 · price: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units (see footnote 4). Read SEC document |
| December 06, 2017 Filed Dec 6, 2017 23:51 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $3.52 Strike: $3.52 | $528,000.00 |
DisclosureSEC source: 0001638599-17-001224 · doc4_5125.xml · derivative · entry 1 Patel Mahesh V. · CIK 0001579872 · Director · CEO, President and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-12-06 F1 · derivative.exercise_date: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 6, 2018, while the remaining 2/3 of the shares subject to the award have vesting monthly on a prorata basis over the following two years. Read SEC document |
| January 26, 2017 Filed Jan 31, 2017 02:41 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantRestricted Stock Unit · Derivative | 60,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000130 · doc4_4497.xml · derivative · entry 1 Patel Mahesh V. · CIK 0001579872 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2027-01-25 F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit F2 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021. Read SEC document |
| December 07, 2016 Filed Dec 8, 2016 15:49 UTC | Lipocine Inc. LPCN · Entity 7696 | GrantStock Option (Right to Buy) · Derivative | 140,000 | $3.61 Strike: $3.61 | $505,400.00 |
DisclosureSEC source: 0001638599-16-001675 · doc4_4384.xml · derivative · entry 1 Patel Mahesh V. · CIK 0001579872 · Director · President, CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2026-12-07 F1 · derivative.exercise_date: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 7, 2017, while the remaining 2/3 of the shares subject to the award vesting monthly on a prorata basis over the following two years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.